Literature DB >> 25324445

Randomized, double-blind, placebo-controlled study to investigate the pharmacodynamic interaction of 5-HT3 antagonist ondansetron and paracetamol in postoperative patients operated in an ENT department under local anesthesia.

Uma A Bhosale, Rahul Khobragade, Chetana Naik, Radha Yegnanarayan, Jyoti Kale.   

Abstract

BACKGROUND: The preclinical incision pain models and clinical studies in healthy volunteers have demonstrated the central serotonergic analgesic mechanism, paracetamol analgesia. This has been evidenced by raised serotonin concentrations in the brain following paracetamol administration in a few studies. The inhibition of paracetamol analgesia by 5-HT3 antagonists suggests that this analgesia is 5-HT3 mediated. However, in a few studies, 5-HT3 antagonists themselves exhibited an analgesic action. Various studies in this context stated intricate results. The present study was intended to understand the pharmacodynamic interaction between paracetamol and ondansetron in postoperative patients.
METHODS: This randomized clinical trial included 32 postoperative cases of either sex, ages between 18 and 70 years. The patients were randomly allocated into the placebo and test groups and received respective treatment at the end of surgery. The pain score was recorded using Visual Analogue Scale (VAS) and Face, Legs, Activity, Cry, Consolability (FLACC) behavioral scale at awakening and every 30 min for the next 3 h. The postoperative rescue analgesic consumption for 24 h was recorded. The data were analyzed using OpenEpi and SciStatCalc statistical software.
RESULTS: A significantly higher pain score was observed in the placebo group postoperatively for 60 min on VAS (p<0.05 and p<0.01), whereas the FLACC behavior scale score was significantly higher at 120 and 150 min (p<0.05). The test group patients were more comfortable throughout the study, and the postoperative analgesic requirement was significantly lesser (p<0.05).
CONCLUSIONS: The pharmacodynamic interaction between paracetamol and ondansetron coadministration does not block but instead increase paracetamol analgesia, reduce the postoperative analgesic requirement, and improve the postoperative comfort level.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25324445     DOI: 10.1515/jbcpp-2014-0070

Source DB:  PubMed          Journal:  J Basic Clin Physiol Pharmacol        ISSN: 0792-6855


  5 in total

1.  Transmission pathways and mediators as the basis for clinical pharmacology of pain.

Authors:  Daniel R Kirkpatrick; Dan M McEntire; Tyler A Smith; Nicholas P Dueck; Mitchell J Kerfeld; Zakary J Hambsch; Taylor J Nelson; Mark D Reisbig; Devendra K Agrawal
Journal:  Expert Rev Clin Pharmacol       Date:  2016-07-04       Impact factor: 5.045

2.  Comparative Pre-Emptive Analgesic Efficacy Study of Novel Antiepileptic Agents Lamotrigine and Topiramate in Patients Undergoing Major Surgeries at a Tertiary Care Hospital: A Randomized Double Blind Clinical Trial.

Authors:  Ankush Gupta; Uma A Bhosale; Priyank Shah; Radha Yegnanarayan; Shalini Sardesai
Journal:  Ann Neurosci       Date:  2016-09-09

3.  Paracetamol versus Paracetamol Plus Ondansetron on Acute Postoperative Pain.

Authors:  Mohamad Aryafar; Mahnaz Narimani Zamanabadi; Kourosh Farazmehr; Giti Dehghanmanshadi; Sepideh Davoodinejad; Farshid Gholami
Journal:  Surg J (N Y)       Date:  2021-12-15

4.  Repeated tender point injections of granisetron alleviate chronic myofascial pain--a randomized, controlled, double-blinded trial.

Authors:  Nikolaos Christidis; Shahin Omrani; Lars Fredriksson; Mattias Gjelset; Sofia Louca; Britt Hedenberg-Magnusson; Malin Ernberg
Journal:  J Headache Pain       Date:  2015-12-03       Impact factor: 7.277

5.  A Randomized Double-Blind Placebo-Controlled Study to Compare Preemptive Analgesic Efficacy of Novel Antiepileptic Agent Lamotrigine in Patients Undergoing Major Surgeries.

Authors:  Priyank Shah; Uma A Bhosale; Ankush Gupta; Radha Yegnanarayan; Shalini Sardesai
Journal:  N Am J Med Sci       Date:  2016-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.